title: [Efficacy and toxicity of aminoglycoside therapy in the elderly: combined effect of both once-daily regimen and therapeutic drug monitoring].
abstract: This study was aimed to compare with previous results (Grillot et al., 1994), the efficacy of amikacin adaptive optimal control in a geriatric hospital.
  
  
  METHODS
  During six months, 32 patients (aged of 82 +/- 8 years) were included versus 51 during two years (aged of 80 +/- 5). The mean age was not different between the two populations (NS, Student test). They received amikacin initial dosage of 17.7 +/- 5.1 mg/kg/d (vs 13.3 +/- 3.5 for the reference study) and maintenance dosage of 15.1 +/- 4.8 mg/kg/d (vs 11.8 +/- 5.1 for the reference study).
  
  
  METHODS
  Two efficacy outcomes (E1 and E2) and 1 toxicity outcome (T) were taken into account: E1 estimated the effect of adaptive control on maximal drug level, E2: overall recovery. Toxicity outcome was used: T the nephrotoxicity (increasing creatininémia over 44 mumol/l).
  
  
  RESULTS
  All the results are given versus the reference study. 57.6% versus 29.4% of adaptive strategy were once-a-day. E1: Chi square test show that initial dosage and maintenance dosage are greater our study than the previous one (p < 0.05: 78.8% versus 5.9% for initial dosage, 84.4% versus 13.8% for maintenance dosage). E2: 73.6% overall of recovery versus 77% (NS, Chi square test). T: 94% versus 85% (p < 0.05, Chi square test) of creatininemia variation are lower than 44 mumol/l. Duration of treatment is 9.8 +/- 4.8 versus 15 +/- 9 days (p < 0.5, Student test).
  
  
  CONCLUSIONS
  Once-a-day strategy in amikacin therapeutic regimen is no more efficient but decreases toxicity and duration treatment.
authors.affiliation: ADCAPT, Hôpital A. Charial, 40, avenue de la Table de Pierre, 69340 Francheville, Hospices Civils de Lyon, Lyon, France. frfoltz@ch-macon.fr
authors.forename: F
authors.initials: F
authors.lastname: Foltz
authors.forename: M
authors.initials: M
authors.lastname: Ducher
authors.forename: F
authors.initials: F
authors.lastname: Rougier
authors.forename: S
authors.initials: S
authors.lastname: Coudray
authors.forename: Y
authors.initials: Y
authors.lastname: Bourhis
authors.forename: M
authors.initials: M
authors.lastname: Druguet
authors.forename: P
authors.initials: P
authors.lastname: Maire
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000583:Amikacin / Q000008:administration & dosage / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008297:Male; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000583:Amikacin